Abbott (ABT) Tops Q1 EPS by 2c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
Go back to Abbott (ABT) Tops Q1 EPS by 2c, Offers Guidance
April 16, 2025 11:38 AM EDT
Evercore ISI analyst Vijay Kumar raised the price target on Abbott Labs (NYSE: ABT) to $140.00 (from $138.00) while maintaining a Outperform rating.
The analyst comments "Thesis Update: In an environment where uncertainty is the dominating theme, ability to protect bottom-line should be appreciated.... More
April 16, 2025 8:47 AM EDT
Stifel analyst Rick Wise reiterated a Buy rating and $135.00 price target on Abbott Labs (NYSE: ABT).
The analyst comments "From our perspective, Abbott's first quarter report contained few surprises, both to the upside or the downside. First quarter 2025 numbers came in largely in-line with our own projections and Consensus estimates. Reported sales at $10.36B (+6.9% y/y) were in-line with our $10.35B... More
April 16, 2025 8:46 AM EDT
BTIG analyst Marie Thibault reiterated a Buy rating and $140.00 price target on Abbott Labs (NYSE: ABT).
The analyst comments "With adj. EPS two cents above expectations despite a minor sales miss, we think this was a solid quarter from Abbott. We breathe a sigh of relief to see ABT reaffirm its 2025 guide for sales, adj. operating margin, and adj. EPS. We think this matters most to investors. The company reported Q1 total revenue $10.358B (+6.9 y/y org. and +4.0% y/y rep.) that was ~$50M below consensus of $10.407B. Results were helped... More
